Navigation Links
ERT Announces Clearance from German Federal Cartel Office
Date:6/6/2012

sting in high quality companies for more than 20 years. Based in San Francisco, Genstar works in partnership with its management teams and its network of operating executives and strategic advisors to transform its portfolio companies into industry-leading businesses.  Genstar has more than $3 billion of committed capital under management and targets investments focused on selected sectors within the life science, healthcare services, software and software services, insurance and financial services, and industrial technology industries.

Forward-Looking Statements

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties, which could cause actual results to differ materially from those expressed or implied from such statements. These risks and uncertainties include, without limitation, the timing of the special meeting of stockholders.  Other risks and uncertainties that may affect forward-looking statements are described in the "Risk Factors" section and elsewhere in the company's Annual Report on Form 10-K as filed with the Securities and Exchange Commission (SEC) on March 2, 2012. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.  ERT's ability to complete the transaction is dependent upon stockholder approval and other customary closing conditions, not all of which are within the control of ERT or Genstar.

Additional Information and Where to Find It

ERT has filed a definitive proxy statement with the SEC. ERT'S SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT BECAUSE IT CONTAINS IMPORTANT INFORMATION. ERT's stockholders will be mailed a copy of the definitive proxy statement and a proxy voting card and may otherwise obtain, without charge, a co
'/>"/>

SOURCE eResearchTechnology, Inc. (ERT)
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
2. American Oriental Bioengineering Inc. Announces Suspension of Trading in its Common Stock and the Initiation of Delisting Proceedings by NYSE
3. SIRO Clinpharm Announces a Fabulous Date With the Dueling Pianos
4. Tris Pharma Announces Approval of First-Ever Generic to Delsym® Dextromethorphan Polistirex Extended-Release Suspension
5. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
6. The Galien Foundation Announces New "Best Medical Technology" Award Category for 2012 Prix Galien USA Awards Program
7. Perrigo Announces FDA Final Approval Of Tris Pharmas Dextromethorphan Polistirex Extended-Release Oral Suspension
8. Hybrid Fuels, Inc. Announces Name Change to Nouveau Life Pharmaceuticals, Inc.
9. Regeneron Announces June 2012 Investor Conference Presentations
10. AcelRx Pharmaceuticals Announces Pricing of a $10.0 Million PIPE Financing
11. Accelrys Announces Software Licensing Agreement with Gulf Coast Consortia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 WuXi PharmaTech (Cayman) Inc. (NYSE: ... platform company serving the pharmaceutical, biotechnology, and medical device ... and the United States , today ... Tel Aviv area of Israel.  ... broad platform of integrated R&D services to local customers. ...
(Date:10/30/2014)... Boston Scientific Corporation (NYSE: BSX ... Suisse Annual Healthcare Conference on Tuesday, November 11, 2014 ... Brennan , executive vice president and chief financial officer, ... approximately 8:00 a.m. PT followed by a question and ... presentation and question and answer session will be available ...
(Date:10/30/2014)... , Oct. 30, 2014   ViaDerma, Inc. ... to bringing new products to market, has recently ... TetraStem. TetraStem is a topical liquid tetracycline-based antibiotic ... that can convert oral medication active ingredients into ... a first aid antibiotic to help prevent skin ...
Breaking Medicine Technology:WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax 2Boston Scientific To Participate In 2014 Credit Suisse Annual Healthcare Conference 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3
... , FRAZER, Pa., ... announced that it has filed a lawsuit in U.S. District ... of U.S. Patent Nos. 7,132,570 (the ",570 Patent"), 7,297,346 (the ... product NUVIGIL® (armodafinil) Tablets [C-IV]. Cephalon has a three-year ...
... , NEW ... market research report is available in its catalogue: , ... , http://www.reportlinker.com/p0164248/Pharmaceutical-Contract-Manufacturing---Global-Market-Trends.html ... form of increasing competition in generic markets, rising cost ...
Cached Medicine Technology:Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 2Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 3Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 4Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 2Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 3Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 4Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 5
(Date:10/30/2014)... Graphics, coding, typography and search engine optimization– ... of web design and require thorough knowledge to create ... to create a website can be as easy as ... reviews and Facebook posts all accumulate on a multiple ... evolution of how a business can develop a website," ...
(Date:10/30/2014)... 30, 2014 High efficacy and ... in the medical-grade skin care domain: Cosmederm, the ... uniquely potent topical dermatological products, today announces the ... ) with patented COSMEDERM®-7 anti-irritant technology. , ... (50% and 70%) and a low pH (pH ...
(Date:10/30/2014)... October 30, 2014 PreDiabetes Centers ... PreD Store shoppers with a supply of sugardown®, ... to reduce post-meal blood sugar spikes. Learning how to ... an important part of a diabetes prevention plan. , ... receive one complimentary tube of sugardown. The offer expires ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Radio listeners ... raising questions about the impact of traditional radio commercials ... method most likely to influence a purchasing decision. , ... of 525 consumers conducted by radio marketing company CRN ... categories, isolating the results of respondents who indicated they ...
(Date:10/30/2014)... Tara Haelle HealthDay Reporter ... More than 100 genes have been identified that appear ... And researchers say they are on their way ... contribute to the disorder. Autism spectrum disorders include ... social difficulties and repetitive behaviors. An estimated one in ...
Breaking Medicine News(10 mins):Health News:Facebook Websites In Thirty-Seconds 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3
... Study highlights:, - A blood test recently approved ... better than tests currently used in the,United States., ... mortality in these,patients, which should allow healthcare providers to ... NEW ORLEANS, Nov. 11 A new blood test,identifies ...
... NEW ORLEANS, Nov. 11 A veteran ... Association Howard L.,Lewis Achievement Award for excellence ... Stiles of Freemont, Calif., was honored for ... clinical, economic,political, ethical and cultural implications of ...
... BROOK, Ill., Nov. 11 Over $3.2 million ... days by members of the University,HealthSystem Consortium,s (UHC) ... tool. With the new, easy-to-use UHC,Interactive WorkPlan, materials ... the intuitive reports to identify, analyze, and act ...
... (NEWARK, N.J., Nov. 11, 2008) The F.M. Kirby Foundation ... of Nursing at Rutgers, The State University of New Jersey, ... New Jersey residents. , The grant will also fund the ... research and service in the best academic tradition, said Interim ...
... the treatment of erectile dysfunction and pulmonary hypertension ... of the type-5 phosphodiesterase. The type-5 phosphodiesterase is ... of sildenafil on splanchnic blood flow and portal ... led by Otto Clemmesen from Denmark addresses this ...
... Nov. 11 /PRNewswire-FirstCall/ - SXC Health Solutions Corp.,("SXC" ... SXC), a leading provider of,pharmacy benefits management services, ... the Yale Club in New York City on ... 8:00 a.m. until approximately,11:00 a.m. eastern time and ...
Cached Medicine News:Health News:New Blood Test Better Identifies Heart Failure Patients in ER 2Health News:New Blood Test Better Identifies Heart Failure Patients in ER 3Health News:New Blood Test Better Identifies Heart Failure Patients in ER 4Health News:SpendLINK(TM) Enhancements Help Academic Medical Centers Easily Track Savings Opportunities 2Health News:SXC Health Solutions to host analyst and institutional investor event 2
... is enzyme immunoassay kit for the ... concentration in serum. Enzyme immunoassay (EIA) ... many protein hormones in body fluids ... rapid and specific assay. This enzyme ...
SHIONORIA BNP,is a reagent used in the measurement of blood BNP. The blood BNP test allows accurate estimation of coronary functions....
... method for the semi-quantitative determination of ... human serum. The results of the ... an aid in the diagnosis of ... with elevated anti-neutrophil cytoplasmic antibodies (P-ANCA) ...
... The determination of Ang ... in monitoring the pharmacological effect ... variety of angiotensin converting enzyme ... II receptor antagonists as well ...
Medicine Products: